Combining low-dose chemotherapies is a strategy for designing less toxic and more potent childhood cancer treatments. We examined the effects of combining the novel thiosemicarbazones, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), or its analog, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), with the standard chemotherapies, celecoxib (CX), etoposide (ETO), or temozolomide (TMZ). These combinations were analyzed for synergism to inhibit proliferation of three pediatric tumor cell-types, namely osteosarcoma (Saos-2), medulloblastoma (Daoy) and neuroblastoma (SH-SY5Y). In terms of mechanistic dissection, this study discovered novel thiosemicarbazone targets not previously identified and which are important for considering possible drug combinations. In this case, DpC and Dp44mT caused: (1) up-regulation of a major protein target of CX, namely cyclooxygenase-2 (COX-2); (2) down-regulation of the DNA repair protein, O6-methylguanine DNA methyltransferase (MGMT), which is known to affect TMZ resistance; (3) down-regulation of mismatch repair (MMR) proteins, MSH2 and MSH6, in Daoy and SH-SY5Y cells; and (4) down-regulation in all three cell-types of the MMR repair protein, MLH1, and also topoisomerase 2α (Topo2α), the latter of which is an ETO target. While thiosemicarbazones up-regulate the metastasis suppressor, NDRG1, in adult cancers, it is demonstrated herein for the first time that they induce NDRG1 in all three pediatric tumor cell-types, validating its role as a potential target. In fact, siRNA studies indicated that NDRG1 was responsible for MGMT down-regulation that may prevent TMZ resistance. Examining the effects of combining thiosemicarbazones with CX, ETO, or TMZ, the most promising synergism was obtained using CX. Of interest, a positive relationship was observed between NDRG1 expression of the cell-type and the synergistic activity observed in the combination of thiosemicarbazones and CX. These studies identify novel thiosemicarbazone targets relevant to childhood cancer combination chemotherapy.

Department of Experimental Biology Faculty of Science Masaryk University 61137 Brno Czech Republic

Department of Pediatric Oncology University Hospital Brno and Faculty of Medicine Masaryk University 66263 Brno Czech Republic

Griffith Institute for Drug Discovery Centre for Cancer Cell Biology and Drug Discovery Griffith University Brisbane Queensland 4111 Australia

International Clinical Research Center St Anne's University Hospital 65691 Brno Czech Republic

Zobrazit více v PubMed

Miller K.D., Siegel R.L., Lin C.C., Mariotto A.B., Kramer J.L., Rowland J.H., Stein K.D., Alteri R., Jemal A. Cancer treatment and survivorship statistics, 2016. CA. Cancer J. Clin. 2016;66:271–289. doi: 10.3322/caac.21349. PubMed DOI

Richardson D.R., Persson L., Xu X. Molecular pharmacology of the interaction of anthracyclines with iron. Mol. Pharmacol. 2005;68:1–11. doi: 10.1124/mol.105.013383. PubMed DOI

Oeffinger K.C., Mertens A.C., Sklar C.A. Chronic health conditions in adult survivors of childhood cancer. Oncol. Times. 2007;29:26. doi: 10.1097/01.COT.0000265629.30194.8e. PubMed DOI

Sterba J., Valik D., Mudry P., Kepak T., Pavelka Z., Bajciova V., Zitterbart K., Kadlecova V., Mazanek P. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: Single-center pilot study. Onkologie. 2006;29:308–313. doi: 10.1159/000093474. PubMed DOI

Zapletalova D., André N., Deak L., Kyr M., Bajciova V., Mudry P., Dubska L., Demlova R., Pavelka Z., Zitterbart K., et al. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: A multicenter experience. Oncology. 2012;82:249–260. doi: 10.1159/000336483. PubMed DOI

Yuan J., Lovejoy D.B., Richardson D.R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: In vitro and in vivo assessment. Blood. 2004;104:1450–1458. doi: 10.1182/blood-2004-03-0868. PubMed DOI

Whitnall M., Howard J., Ponka P., Richardson D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. USA. 2006;103:14901–14906. doi: 10.1073/pnas.0604979103. PubMed DOI PMC

Richardson D.R., Tran E.H., Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood. 1995;86:4295–4306. doi: 10.1182/blood.V86.11.4295.bloodjournal86114295. PubMed DOI

Lovejoy D.B., Richardson D.R. Novel “hybrid” iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood. 2002;100:666–676. doi: 10.1182/blood.V100.2.666. PubMed DOI

Liu W., Xing F., Iiizumi-Gairani M., Okuda H., Watabe M., Pai S.K., Pandey P.R., Hirota S., Kobayashi A., Mo Y.-Y., et al. N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol. Med. 2012;4:93–108. doi: 10.1002/emmm.201100190. PubMed DOI PMC

Jansson P.J., Yamagishi T., Arvind A., Seebacher N., Gutierrez E., Stacy A., Maleki S., Sharp D., Sahni S., Richardson D.R. Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp) J. Biol. Chem. 2015;290:9588–9603. doi: 10.1074/jbc.M114.631283. PubMed DOI PMC

Guo Z.-L., Richardson D.R., Kalinowski D.S., Kovacevic Z., Tan-Un K.C., Chan G.C.-F. The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms. J. Hematol. Oncol. J. Hematol. Oncol. 2016;9:98. doi: 10.1186/s13045-016-0330-x. PubMed DOI PMC

Lee J.-C., Chiang K.-C., Feng T.-H., Chen Y.-J., Chuang S.-T., Tsui K.-H., Chung L.-C., Juang H.-H. The iron chelator, Dp44mT, effectively inhibits human oral squamous cell carcinoma cell growth in vitro and in vivo. Int. J. Mol. Sci. 2016;17:1435. doi: 10.3390/ijms17091435. PubMed DOI PMC

Li P., Zheng X., Shou K., Niu Y., Jian C., Zhao Y., Yi W., Hu X., Yu A. The iron chelator Dp44mT suppresses osteosarcoma’s proliferation, invasion and migration: In vitro and in vivo. Am. J. Transl. Res. 2016;8:5370–5385. PubMed PMC

Kovacevic Z., Chikhani S., Lovejoy D.B., Richardson D.R. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: A new strategy for the treatment of pancreatic cancer. Mol. Pharmacol. 2011;80:598–609. doi: 10.1124/mol.111.073627. PubMed DOI

Lovejoy D.B., Sharp D.M., Seebacher N., Obeidy P., Prichard T., Stefani C., Basha M.T., Sharpe P.C., Jansson P.J., Kalinowski D.S., et al. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J. Med. Chem. 2012;55:7230–7244. doi: 10.1021/jm300768u. PubMed DOI

Le N.T.V., Richardson D.R. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: A link between iron metabolism and proliferation. Blood. 2004;104:2967–2975. doi: 10.1182/blood-2004-05-1866. PubMed DOI

Richardson D.R., Sharpe P.C., Lovejoy D.B., Senaratne D., Kalinowski D.S., Islam M., Bernhardt P.V. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J. Med. Chem. 2006;49:6510–6521. doi: 10.1021/jm0606342. PubMed DOI

Lovejoy D.B., Jansson P.J., Brunk U.T., Wong J., Ponka P., Richardson D.R. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res. 2011;71:5871–5880. doi: 10.1158/0008-5472.CAN-11-1218. PubMed DOI

Stacy A.E., Palanimuthu D., Bernhardt P.V., Kalinowski D.S., Jansson P.J., Richardson D.R. Zinc(II)–thiosemicarbazone complexes are localized to the lysosomal compartment where they transmetallate with copper ions to induce cytotoxicity. J. Med. Chem. 2016;59:4965–4984. doi: 10.1021/acs.jmedchem.6b00238. PubMed DOI

Seebacher N.A., Richardson D.R., Jansson P.J. A mechanism for overcoming P-glycoprotein-mediated drug resistance: Novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC. Cell Death Dis. 2016;7:e2510. doi: 10.1038/cddis.2016.381. PubMed DOI PMC

Kovacevic Z., Menezes S.V., Sahni S., Kalinowski D.S., Bae D.-H., Lane D.J.R., Richardson D.R. The metastasis suppressor, N-MYC downstream-regulated gene-1 (NDRG1), down-regulates the ErbB family of receptors to inhibit downstream oncogenic signaling pathways. J. Biol. Chem. 2016;291:1029–1052. doi: 10.1074/jbc.M115.689653. PubMed DOI PMC

Menezes S.V., Kovacevic Z., Richardson D.R. The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6. J. Biol. Chem. 2019;294:4045–4064. doi: 10.1074/jbc.RA118.006279. PubMed DOI PMC

Park K.C., Geleta B., Leck L.Y.W., Paluncic J., Chiang S., Jansson P.J., Kovacevic Z., Richardson D.R. Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding. J. Biol. Chem. 2020;295:481–503. doi: 10.1074/jbc.RA119.011341. PubMed DOI PMC

Kovacevic Z., Chikhani S., Lui G.Y.L., Sivagurunathan S., Richardson D.R. The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid. Redox Signal. 2013;18:874–887. doi: 10.1089/ars.2011.4273. PubMed DOI

Lui G.Y.L., Kovacevic Z., Menezes S., Kalinowski D.S., Merlot A.M., Sahni S., Richardson D.R. Novel thiosemicarbazones regulate the signal transducer and activator of transcription 3 (STAT3) pathway: Inhibition of constitutive and interleukin 6 (IL6)-induced activation by iron depletion. Mol. Pharmacol. 2015 doi: 10.1124/mol.114.096529. PubMed DOI

Chen Z., Zhang D., Yue F., Zheng M., Kovacevic Z., Richardson D.R. The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1) J. Biol. Chem. 2012;287:17016–17028. doi: 10.1074/jbc.M112.350470. PubMed DOI PMC

Menezes S.V., Fouani L., Huang M.L.H., Geleta B., Maleki S., Richardson A., Richardson D.R., Kovacevic Z. The metastasis suppressor, NDRG1, attenuates oncogenic TGF-β and NF-κB signaling to enhance membrane E-cadherin expression in pancreatic cancer cells. Carcinogenesis. 2019;40:805–818. doi: 10.1093/carcin/bgy178. PubMed DOI

Jin R., Liu W., Menezes S., Yue F., Zheng M., Kovacevic Z., Richardson D.R. The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of β-catenin through mechanisms involving FRAT1 and PAK4. J. Cell Sci. 2014;127:3116–3130. doi: 10.1242/jcs.147835. PubMed DOI

Gutierrez E., Richardson D.R., Jansson P.J. The anticancer agent di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: Persistent induction of autophagosome synthesis and impairment of lysosomal integrity. J. Biol. Chem. 2014;289:33568–33589. doi: 10.1074/jbc.M114.599480. PubMed DOI PMC

Potuckova E., Jansova H., Machacek M., Vavrova A., Haskova P., Tichotova L., Richardson V., Kalinowski D.S., Richardson D.R., Simunek T. Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs. PLoS ONE. 2014;9:e88754. doi: 10.1371/journal.pone.0088754. PubMed DOI PMC

Maqbool S.N., Lim S.C., Park K.C., Hanif R., Richardson D.R., Jansson P.J., Kovacevic Z. Overcoming tamoxifen resistance in oestrogen receptor-positive breast cancer using the novel thiosemicarbazone anti-cancer agent, DpC. Br. J. Pharmacol. 2020;177:2365–2380. doi: 10.1111/bph.14985. PubMed DOI PMC

Jendrossek V. Targeting apoptosis pathways by celecoxib in cancer. Cancer Lett. 2013;332:313–324. doi: 10.1016/j.canlet.2011.01.012. PubMed DOI

Thomas A., Tanaka M., Trepel J., Reinhold W.C., Rajapakse V.N., Pommier Y. Temozolomide in the era of precision medicine. Cancer Res. 2017;77:823–826. doi: 10.1158/0008-5472.CAN-16-2983. PubMed DOI PMC

Relling M.V., Boyett J.M., Blanco J.G., Raimondi S., Behm F.G., Sandlund J.T., Rivera G.K., Kun L.E., Evans W.E., Pui C.-H. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood. 2003;101:3862–3867. doi: 10.1182/blood-2002-08-2405. PubMed DOI

Walker J.V., Nitiss J.L. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Investig. 2002;20:570–589. doi: 10.1081/CNV-120002156. PubMed DOI

Schwartzman M.L., Bonazzi A., Mieyal P., Mezentsev A., Abraham N.G., Dunn M.W. COX-2 lack of function in hypoxia-induced ocular surface inflammation. Thromb. Res. 2003;110:293–298. doi: 10.1016/S0049-3848(03)00415-8. PubMed DOI

Hausmann A., Lee J., Pantopoulos K. Redox control of iron regulatory protein 2 stability. FEBS Lett. 2011;585:687–692. doi: 10.1016/j.febslet.2011.01.036. PubMed DOI

Saxena N., Maio N., Crooks D.R., Ricketts C.J., Yang Y., Wei M.-H., Fan T.W.-M., Lane A.N., Sourbier C., Singh A., et al. SDHB-deficient cancers: The role of mutations that impair iron sulfur cluster delivery. JNCI J. Natl. Cancer Inst. 2016;108 doi: 10.1093/jnci/djv287. PubMed DOI PMC

Park Y.-K., Hong H., Jang B.-C. Transcriptional and translational regulation of COX-2 expression by cadmium in C6 glioma cells. Int. J. Mol. Med. 2012;30:960–966. doi: 10.3892/ijmm.2012.1052. PubMed DOI

Arico S., Pattingre S., Bauvy C., Gane P., Barbat A., Codogno P., Ogier-Denis E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Biol. Chem. 2002;277:27613–27621. doi: 10.1074/jbc.M201119200. PubMed DOI

Park K.C., Menezes S.V., Kalinowski D.S., Sahni S., Jansson P.J., Kovacevic Z., Richardson D.R. Identification of differential phosphorylation and sub-cellular localization of the metastasis suppressor, NDRG1. Biochim. Biophys. Acta Mol. Basis Dis. 2018;1864:2644–2663. doi: 10.1016/j.bbadis.2018.04.011. PubMed DOI

Sahni S., Park K.C., Kovacevic Z., Richardson D.R. Two mechanisms involving the autophagic and proteasomal pathways process the metastasis suppressor protein, N-myc downstream regulated gene 1. Biochim. Biophys. Acta Mol. Basis Dis. 2019;1865:1361–1378. doi: 10.1016/j.bbadis.2019.02.008. PubMed DOI

Happold C., Roth P., Wick W., Schmidt N., Florea A.-M., Silginer M., Reifenberger G., Weller M. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J. Neurochem. 2012;122:444–455. doi: 10.1111/j.1471-4159.2012.07781.x. PubMed DOI

Yip S., Miao J., Cahill D.P., Iafrate A.J., Aldape K., Nutt C.L., Louis D.N. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2009;15:4622–4629. doi: 10.1158/1078-0432.CCR-08-3012. PubMed DOI PMC

Liu L., Markowitz S., Gerson S.L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res. 1996;56:5375–5379. PubMed

Kunkel T.A., Erie D.A. DNA mismatch repair. Annu. Rev. Biochem. 2005;74:681–710. doi: 10.1146/annurev.biochem.74.082803.133243. PubMed DOI

Montecucco A., Biamonti G. Cellular response to etoposide treatment. Cancer Lett. 2007;252:9–18. doi: 10.1016/j.canlet.2006.11.005. PubMed DOI

Merlot A.M., Kalinowski D.S., Kovacevic Z., Jansson P.J., Sahni S., Huang M.L.-H., Lane D.J.R., Lok H., Richardson D.R. Exploiting cancer metal metabolism using anti-cancer metal-binding agents. Curr. Med. Chem. 2019;26:302–322. doi: 10.2174/0929867324666170705120809. PubMed DOI

Park K.C., Paluncic J., Kovacevic Z., Richardson D.R. Pharmacological targeting and the diverse functions of the metastasis suppressor, NDRG1, in cancer. Free Radic. Biol. Med. 2020;157:154–175. doi: 10.1016/j.freeradbiomed.2019.05.020. PubMed DOI

Dixon K.M., Lui G.Y.L., Kovacevic Z., Zhang D., Yao M., Chen Z., Dong Q., Assinder S.J., Richardson D.R. Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. Br. J. Cancer. 2013;108:409–419. doi: 10.1038/bjc.2012.582. PubMed DOI PMC

Lim S.C., Jansson P.J., Assinder S.J., Maleki S., Richardson D.R., Kovacevic Z. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance. FASEB J. 2020 doi: 10.1096/fj.201903167R. PubMed DOI

Xu Y.-X., Zeng M.-L., Yu D., Ren J., Li F., Zheng A., Wang Y.-P., Chen C., Tao Z.-Z. In vitro assessment of the role of DpC in the treatment of head and neck squamous cell carcinoma. Oncol. Lett. 2018;15:7999–8004. doi: 10.3892/ol.2018.8279. PubMed DOI PMC

Jansson P.J., Kalinowski D.S., Lane D.J.R., Kovacevic Z., Seebacher N.A., Fouani L., Sahni S., Merlot A.M., Richardson D.R. The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the “Triad of Death” in cancer by Di-2-pyridylketone thiosemicarbazones. Pharmacol. Res. 2015;100:255–260. doi: 10.1016/j.phrs.2015.08.013. PubMed DOI

Zarghi A., Arfaei S. Selective COX-2 inhibitors: A review of their structure-activity relationships. Iran. J. Pharm. Res. IJPR. 2011;10:655–683. PubMed PMC

Rudner J., Elsaesser S.J., Müller A.-C., Belka C., Jendrossek V. Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis. Biochem. Pharmacol. 2010;79:10–20. doi: 10.1016/j.bcp.2009.07.021. PubMed DOI

Johnson A.J., Hsu A.-L., Lin H.-P., Song X., Chen C.-S. The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: A plausible link with its anti-tumour effect and cardiovascular risks. Biochem. J. 2002;366:831–837. doi: 10.1042/bj20020279. PubMed DOI PMC

Kovacevic Z., Sivagurunathan S., Mangs H., Chikhani S., Zhang D., Richardson D.R. The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis. 2011;32:732–740. doi: 10.1093/carcin/bgr046. PubMed DOI

Sun J., Zhang D., Bae D.-H., Sahni S., Jansson P., Zheng Y., Zhao Q., Yue F., Zheng M., Kovacevic Z., et al. Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis. 2013;34:1943–1954. doi: 10.1093/carcin/bgt163. PubMed DOI

Ma W., Na M., Tang C., Wang H., Lin Z. Overexpression of N-myc downstream-regulated gene 1 inhibits human glioma proliferation and invasion via phosphoinositide 3-kinase/AKT pathways. Mol. Med. Rep. 2015;12:1050–1058. doi: 10.3892/mmr.2015.3492. PubMed DOI PMC

Kaina B., Christmann M., Naumann S., Roos W.P. MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair. 2007;6:1079–1099. doi: 10.1016/j.dnarep.2007.03.008. PubMed DOI

Gerson S.L. Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 2002;20:2388–2399. doi: 10.1200/JCO.2002.06.110. PubMed DOI

Woo P.Y.M., Li Y., Chan A.H.Y., Ng S.C.P., Loong H.H.F., Chan D.T.M., Wong G.K.C., Poon W.-S. A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase. Glioma. 2019;2:68. doi: 10.4103/glioma.glioma_3_19. DOI

Duguid E.M., Rice P.A., He C. The structure of the human AGT protein bound to DNA and its implications for damage detection. J. Mol. Biol. 2005;350:657–666. doi: 10.1016/j.jmb.2005.05.028. PubMed DOI

Wickström M., Dyberg C., Milosevic J., Einvik C., Calero R., Sveinbjörnsson B., Sandén E., Darabi A., Siesjö P., Kool M., et al. Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nat. Commun. 2015;6:8904. doi: 10.1038/ncomms9904. PubMed DOI PMC

Alexander B.M., Pinnell N., Wen P.Y., D’Andrea A. Targeting DNA repair and the cell cycle in glioblastoma. J. Neurooncol. 2012;107:463–477. doi: 10.1007/s11060-011-0765-4. PubMed DOI

Rao V.A., Klein S.R., Agama K.K., Toyoda E., Adachi N., Pommier Y., Shacter E.B. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res. 2009;69:948–957. doi: 10.1158/0008-5472.CAN-08-1437. PubMed DOI PMC

Yalowich J.C., Wu X., Zhang R., Kanagasabai R., Hornbaker M., Hasinoff B.B. The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα. Biochem. Pharmacol. 2012;84:52–58. doi: 10.1016/j.bcp.2012.03.021. PubMed DOI PMC

Nitiss J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer. 2009;9:338–350. doi: 10.1038/nrc2607. PubMed DOI PMC

Emanuelli A., Borroni A.P., Apel-Sarid L., Shah P.A., Ayyathan D.M., Koganti P., Levy-Cohen G., Blank M. Smurf2-mediated stabilization of DNA topoisomerase IIα controls genomic integrity. Cancer Res. 2017;77:4217–4227. doi: 10.1158/0008-5472.CAN-16-2828. PubMed DOI

Krzyzankova M., Chovanova S., Chlapek P., Radsetoulal M., Neradil J., Zitterbart K., Sterba J., Veselska R. LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2014;35:7617–7627. doi: 10.1007/s13277-014-2019-5. PubMed DOI

Chou T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006;58:621–681. doi: 10.1124/pr.58.3.10. PubMed DOI

Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells

Iron-Chelation Treatment by Novel Thiosemicarbazone Targets Major Signaling Pathways in Neuroblastoma